Seer Rises 37% on Acquisition Proposal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Stock futures were mixed ahead of the long weekend as traders considered the weaker-than-expected U.S. nonfarm payrolls for June and what it might mean for the path of rates. Meanwhile, the Nasdaq fell amid continued pressure on technology and semiconductor names. Chip stocks have experienced a notable pullback to begin the second half of the year, suggesting traders are taking profits after a strong run.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Seerup 37% after receiving an unsolicited acquisition proposal from CEO Omid Farokhzad for $2.45 per shareLOWER -Genuine Partsdown 1.1% after Bloomberg reported that O'Reillymade a cash bid for Genuine's auto parts unit
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEER?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEER
About SEER
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Seer CEO Proposes Acquisition at $2.45 per Share, Stock Soars 26%
- Acquisition Proposal Surge: Seer CEO Omid Farokhzad's proposal to acquire all outstanding Class A common stock at $2.45 per share in cash has led to a 26% premarket surge in the company's stock, indicating strong market enthusiasm for the offer.
- Independent Committee Review: The Seer board's decision to form a special committee of independent directors to review the non-binding proposal demonstrates the company's commitment to thoroughly evaluate the offer while safeguarding shareholder interests.
- Additional Rights Assurance: The acquisition proposal includes two separate contingent value rights, aimed at providing shareholders with additional potential returns, which enhances the attractiveness of the offer and may draw more investor interest.
- Positive Market Reaction: The significant rise in Seer’s stock following the acquisition news reflects investor optimism about the company's future prospects, and it may also prompt other potential buyers to consider the company, increasing market competition.
See More
Seer, Inc. Receives Acquisition Proposal
- Acquisition Proposal Overview: Seer, Inc. has received an unsolicited acquisition proposal from CEO Omid Farokhzad, offering $2.45 per share in cash plus two contingent value rights, indicating recognition of the company's future value.
- Board Response: Seer's Board of Directors will establish a Special Committee composed solely of independent directors to evaluate the proposal and other alternatives, ensuring actions taken are in the best interests of the company and its shareholders.
- Advisory Team: The Special Committee will retain independent financial and legal advisors, with Perella Weinberg Partners LP serving as the financial advisor and Wilson Sonsini Goodrich & Rosati providing legal counsel, ensuring a professional and transparent evaluation process.
- Market Impact: While no shareholder action is required at this time, the proposal may influence Seer's stock price and market confidence, reflecting investor interest in the company's future developments.
See More
Seer Inc. Achieves Key Milestones in IP Protection
- Patent Maintenance Success: The European Patent Office has decided to maintain European Patent No. EP4056263, which covers particle-based protein enrichment technology, further solidifying Seer's leadership in proteomics and providing legal protection for future technological advancements.
- ITC Investigation Initiated: The U.S. International Trade Commission has launched an investigation into products from Nanomics Biotechnology Co., Ltd. that allegedly infringe five of Seer's U.S. patents, with Seer seeking to restrict the import and sale of these products in the U.S., demonstrating its proactive stance on intellectual property protection.
- Patent Portfolio Expansion: Seer currently holds over 250 patent applications and issued patents, including 84 patents granted worldwide, which significantly supports the intellectual property integral to its Proteograph® Product Suite.
- Industry Recognition Enhanced: The U.S. Patent Trial and Appeal Board confirmed key claims of U.S. Patent No. 11.435,360 on March 23, 2026, further validating Seer's patent estate and enhancing its competitive position in the market.
See More
Seer, Inc. Strengthens IP Portfolio with Key Developments
- Patent Maintenance Decision: The European Patent Office's decision to uphold Patent EP4056263, which covers Seer's particle-based enrichment technology, reinforces its leadership in the proteomics field, likely enhancing market confidence and driving future technology applications.
- U.S. Investigation Initiation: The U.S. International Trade Commission has launched an investigation into Nanomics Biotechnology's products, following Seer's allegations of infringement on five U.S. patents, which, if successful, will restrict Nanomics' sales in the U.S., further solidifying Seer's market position.
- Patent Portfolio Expansion: Seer holds over 250 patent applications and issued patents, including 84 globally granted patents, providing robust intellectual property protection for its Proteograph® product suite, ensuring the uniqueness of its technology and competitive edge in the market.
- Industry Leadership Statement: Seer's CEO Omid Farokhzad emphasized that the strength of the company's IP portfolio will enable it to vigorously defend its innovations, ensuring that the technologies relied upon by customers remain protected, thereby driving continued growth in the proteomics sector.
See More
Seer Inc. Provides Key Information for Upcoming Annual Meeting
- Annual Meeting Announcement: Seer Inc. will hold its Annual Meeting of Stockholders on July 28, 2026, with shareholders as of May 29, 2026, entitled to vote, and the Board recommends using the BLUE proxy card to support the election of seven nominated directors to ensure continuity in the company's strategic execution.
- Director Nomination Controversy: Two activist shareholders have submitted director nominations and acquisition proposals priced below the company's cash and investments, prompting the Board to emphasize the importance of supporting existing members to maintain long-term value and strategic direction.
- Market Leadership Position: Seer's Proteograph® product suite is the only commercial solution capable of standardized, deep, unbiased proteomics at population scale, with over 250 patent applications, highlighting the company's unique positioning and potential growth in the proteomics market.
- Financial Management Effectiveness: Seer's operating expenses declined by 19.3% year-over-year in 2025, with Q1 2026 operating expenses at $18.2 million, significantly reduced from $22.8 million in Q1 2025, indicating strong financial discipline and capital allocation while accelerating product launches.
See More
Seer Urges Shareholders to Vote for Board Nominees Amid Proxy Fight
- Annual Meeting Announcement: Seer is set to hold its Annual Meeting on July 28, 2026, with shareholders required to register by May 29 to vote, and the Board recommends supporting seven nominated directors to ensure the continuity of the company's strategic direction.
- Strategic Execution Progress: Seer has made significant strides in the deep unbiased proteomics market, expanding adoption of its Proteograph® platform and advancing large-scale population studies, demonstrating strong momentum in scientific validation and customer adoption.
- Financial Discipline Management: Seer has reduced operating expenses by approximately 4.3% and 19.3% year-over-year between 2023 and 2025, while accelerating product innovation and launches, showcasing the company's ability to balance cost control with growth.
- Board Independence: Seer's Board consists of seasoned industry experts, ensuring strategic execution at a critical time, opposing the nominations from Radoff and Torok, as their candidates lack relevant experience and may harm shareholder interests.
See More
Seer CEO Proposes Acquisition at $2.45 per Share, Stock Soars 26%
- Acquisition Proposal Surge: Seer CEO Omid Farokhzad's proposal to acquire all outstanding Class A common stock at $2.45 per share in cash has led to a 26% premarket surge in the company's stock, indicating strong market enthusiasm for the offer.
- Independent Committee Review: The Seer board's decision to form a special committee of independent directors to review the non-binding proposal demonstrates the company's commitment to thoroughly evaluate the offer while safeguarding shareholder interests.
- Additional Rights Assurance: The acquisition proposal includes two separate contingent value rights, aimed at providing shareholders with additional potential returns, which enhances the attractiveness of the offer and may draw more investor interest.
- Positive Market Reaction: The significant rise in Seer’s stock following the acquisition news reflects investor optimism about the company's future prospects, and it may also prompt other potential buyers to consider the company, increasing market competition.
See More
Seer, Inc. Receives Acquisition Proposal
- Acquisition Proposal Overview: Seer, Inc. has received an unsolicited acquisition proposal from CEO Omid Farokhzad, offering $2.45 per share in cash plus two contingent value rights, indicating recognition of the company's future value.
- Board Response: Seer's Board of Directors will establish a Special Committee composed solely of independent directors to evaluate the proposal and other alternatives, ensuring actions taken are in the best interests of the company and its shareholders.
- Advisory Team: The Special Committee will retain independent financial and legal advisors, with Perella Weinberg Partners LP serving as the financial advisor and Wilson Sonsini Goodrich & Rosati providing legal counsel, ensuring a professional and transparent evaluation process.
- Market Impact: While no shareholder action is required at this time, the proposal may influence Seer's stock price and market confidence, reflecting investor interest in the company's future developments.
See More
Seer Inc. Achieves Key Milestones in IP Protection
- Patent Maintenance Success: The European Patent Office has decided to maintain European Patent No. EP4056263, which covers particle-based protein enrichment technology, further solidifying Seer's leadership in proteomics and providing legal protection for future technological advancements.
- ITC Investigation Initiated: The U.S. International Trade Commission has launched an investigation into products from Nanomics Biotechnology Co., Ltd. that allegedly infringe five of Seer's U.S. patents, with Seer seeking to restrict the import and sale of these products in the U.S., demonstrating its proactive stance on intellectual property protection.
- Patent Portfolio Expansion: Seer currently holds over 250 patent applications and issued patents, including 84 patents granted worldwide, which significantly supports the intellectual property integral to its Proteograph® Product Suite.
- Industry Recognition Enhanced: The U.S. Patent Trial and Appeal Board confirmed key claims of U.S. Patent No. 11.435,360 on March 23, 2026, further validating Seer's patent estate and enhancing its competitive position in the market.
See More
Seer, Inc. Strengthens IP Portfolio with Key Developments
- Patent Maintenance Decision: The European Patent Office's decision to uphold Patent EP4056263, which covers Seer's particle-based enrichment technology, reinforces its leadership in the proteomics field, likely enhancing market confidence and driving future technology applications.
- U.S. Investigation Initiation: The U.S. International Trade Commission has launched an investigation into Nanomics Biotechnology's products, following Seer's allegations of infringement on five U.S. patents, which, if successful, will restrict Nanomics' sales in the U.S., further solidifying Seer's market position.
- Patent Portfolio Expansion: Seer holds over 250 patent applications and issued patents, including 84 globally granted patents, providing robust intellectual property protection for its Proteograph® product suite, ensuring the uniqueness of its technology and competitive edge in the market.
- Industry Leadership Statement: Seer's CEO Omid Farokhzad emphasized that the strength of the company's IP portfolio will enable it to vigorously defend its innovations, ensuring that the technologies relied upon by customers remain protected, thereby driving continued growth in the proteomics sector.
See More
Seer Inc. Provides Key Information for Upcoming Annual Meeting
- Annual Meeting Announcement: Seer Inc. will hold its Annual Meeting of Stockholders on July 28, 2026, with shareholders as of May 29, 2026, entitled to vote, and the Board recommends using the BLUE proxy card to support the election of seven nominated directors to ensure continuity in the company's strategic execution.
- Director Nomination Controversy: Two activist shareholders have submitted director nominations and acquisition proposals priced below the company's cash and investments, prompting the Board to emphasize the importance of supporting existing members to maintain long-term value and strategic direction.
- Market Leadership Position: Seer's Proteograph® product suite is the only commercial solution capable of standardized, deep, unbiased proteomics at population scale, with over 250 patent applications, highlighting the company's unique positioning and potential growth in the proteomics market.
- Financial Management Effectiveness: Seer's operating expenses declined by 19.3% year-over-year in 2025, with Q1 2026 operating expenses at $18.2 million, significantly reduced from $22.8 million in Q1 2025, indicating strong financial discipline and capital allocation while accelerating product launches.
See More
Seer Urges Shareholders to Vote for Board Nominees Amid Proxy Fight
- Annual Meeting Announcement: Seer is set to hold its Annual Meeting on July 28, 2026, with shareholders required to register by May 29 to vote, and the Board recommends supporting seven nominated directors to ensure the continuity of the company's strategic direction.
- Strategic Execution Progress: Seer has made significant strides in the deep unbiased proteomics market, expanding adoption of its Proteograph® platform and advancing large-scale population studies, demonstrating strong momentum in scientific validation and customer adoption.
- Financial Discipline Management: Seer has reduced operating expenses by approximately 4.3% and 19.3% year-over-year between 2023 and 2025, while accelerating product innovation and launches, showcasing the company's ability to balance cost control with growth.
- Board Independence: Seer's Board consists of seasoned industry experts, ensuring strategic execution at a critical time, opposing the nominations from Radoff and Torok, as their candidates lack relevant experience and may harm shareholder interests.
See More
